(NASDAQ: AXSM) Axsome Therapeutics's forecast annual revenue growth rate of 39.16% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 99.5%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.47%.
Axsome Therapeutics's revenue in 2025 is $561,263,000.On average, 22 Wall Street analysts forecast AXSM's revenue for 2025 to be $32,315,510,493, with the lowest AXSM revenue forecast at $30,284,889,354, and the highest AXSM revenue forecast at $33,755,799,618. On average, 22 Wall Street analysts forecast AXSM's revenue for 2026 to be $50,916,766,400, with the lowest AXSM revenue forecast at $44,384,800,635, and the highest AXSM revenue forecast at $58,277,011,840.
In 2027, AXSM is forecast to generate $77,887,528,800 in revenue, with the lowest revenue forecast at $59,890,216,320 and the highest revenue forecast at $99,514,551,360.